Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Peptide medications for weight loss — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — are FDA-approved GLP-1 receptor agonists that reduce appetite and improve metabolic function. These medications work best when the dosing schedule is built around your body. A custom peptide plan means your physician designs your starting dose, titration speed, and monitoring schedule based on your individual profile — not a standard one-size-fits-all template.
Clinical trials confirm the power of these peptide medications: semaglutide achieved 15% average body weight reduction in the STEP trials, while tirzepatide reached 22.5% in the SURMOUNT trials. A physician-customized plan maximizes your ability to achieve and sustain these results.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Your custom plan begins with a thorough evaluation of your health history, metabolic markers, weight loss goals, and current medications. This profile guides every decision your physician makes — from which peptide to prescribe to how quickly to escalate your dose.
Not every peptide medication is right for every patient. Your physician selects semaglutide, tirzepatide, or liraglutide based on your individual metabolic profile, existing conditions, and therapeutic goals. Custom selection means better-matched therapy and better outcomes.
Your custom peptide plan includes a personalized dosing schedule with built-in flexibility. If your body responds faster or needs more time at a given dose, your physician adjusts the plan accordingly — keeping your therapy optimized at every stage.
Three landmark randomized controlled trials in the New England Journal of Medicine form the evidence base for FDA-approved GLP-1 weight management medications:
Telehealth prescribing of GLP-1 medications is fully legal in all 50 states when conducted by a properly licensed physician through a HIPAA-compliant platform. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are not DEA-scheduled controlled substances — no in-person visit is required by federal or state telehealth law.
Adult obesity rates (CDC Behavioral Risk Factor Surveillance System, 2023) vary significantly across the United States. States with higher obesity prevalence experience the greatest demand for accessible GLP-1 telehealth prescriptions:
Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023. Adult obesity defined as BMI ≥ 30.0.
Select your state to begin your personalized peptide weight loss plan with a licensed physician in your jurisdiction.
Personalized peptide weight loss plans are available to patients in the largest American cities. Find your city and begin.
Your custom peptide plan is built around you — not a generic template. Here is how Made Peptide creates your personalized weight loss plan from the ground up.
Complete a comprehensive health questionnaire covering your weight history, metabolic health, current medications, lifestyle factors, and weight loss goals. This is the raw material your physician uses to build a plan that fits your specific body and situation — not a default protocol.
A board-certified physician reviews your complete health profile and conducts a telehealth consultation. They select the peptide medication best suited to your body, establish a custom dosing schedule with personalized titration milestones, and set clear expectations for your individual weight loss journey.
Your prescribed peptide medication — matched to your custom plan — ships from a licensed US pharmacy to your door within 3-5 business days. From the first dose, your physician monitors your individual response and adjusts the plan as your body progresses. Your plan evolves with you.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Custom peptide plans use only FDA-approved medications: semaglutide (Ozempic for diabetes, Wegovy for weight loss), tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), and liraglutide (Saxenda for weight loss). Your physician selects the most appropriate agent based on your individual health profile, metabolic history, and treatment goals — not a default choice.
A standard prescription gives you a medication with a general dosing guideline. A custom peptide plan gives you a physician-designed roadmap — including your specific starting dose, your personalized titration schedule, individual monitoring checkpoints, and a plan for adjustments based on how your body responds. The result is better tolerability and better outcomes.
Most patients notice appetite reduction and early metabolic changes within the first 2-4 weeks. Meaningful weight reduction typically builds from weeks 4-12 as doses increase to therapeutic levels. Clinical trials show semaglutide achieves 15% average weight reduction at 68 weeks and tirzepatide up to 22.5% at 72 weeks with structured plans.
Absolutely — that is one of the core advantages of a custom plan. If you experience side effects, plateau at a certain dose, or your health situation changes, your physician updates your plan accordingly. Regular telehealth check-ins ensure your peptide therapy remains optimized throughout your treatment.
Yes, when designed and monitored by a licensed physician. Physician customization actually improves safety — because your dosing schedule is calibrated to your tolerance, not a generic timeline. Common side effects like mild nausea are managed proactively through personalized dose titration. All peptide medications in custom plans have been studied in clinical trials involving tens of thousands of patients.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
